Filing Flows › Comparisons › AMRN vs ZVRA
Amarin vs Zevra Therapeutics: AMRN and ZVRA compared
Amarin is the larger company: $39.5M of revenue in its latest quarter (Q3 2026) against $37.8M for Zevra Therapeutics (Q3 2026). Zevra Therapeutics is growing faster (+45% against -20% a year earlier). Zevra Therapeutics is more profitable, with an operating margin of 30.7% against -6.0%.
Where the money goes: AMRN and ZVRA
Amarin (AMRN) · Q3 2026
Amarin, Q3 2026: revenue $39.5M (-20% year over year), operating margin -6.0%, net earnings $245K, operating cash flow $9.2M. The chart follows the revenue to costs, profit and cash.
Zevra Therapeutics (ZVRA) · Q3 2026
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart follows the revenue to costs, profit and cash.
| Amarin (AMRN) | Zevra Therapeutics (ZVRA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $39.5M | $37.8M |
| Revenue growth, Y/Y | -20% | +45% |
| Operating margin | -6.0% | 30.7% |
| Net earnings | $245K | $19.2M |
| Net margin | 0.6% | 50.9% |
| Operating cash flow | $9.2M | $10.0M |
| Free cash flow | — | $9.8M |
| Market value | — | $636M |
| P/E | — | 8.5× |
| Analysts’ mean target | — | $25.25 |
Where the revenue comes from
Amarin
- Product: $36.9M (93%)
- Licensing and Royalty: $2.7M (7%)
Questions
Which is bigger, Amarin or Zevra Therapeutics?
Amarin is the larger company: $39.5M of revenue in its latest quarter (Q3 2026) against $37.8M for Zevra Therapeutics (Q3 2026).
Is Amarin or Zevra Therapeutics growing faster?
Zevra Therapeutics is growing faster (+45% against -20% a year earlier).
Which is more profitable, Amarin or Zevra Therapeutics?
Zevra Therapeutics is more profitable, with an operating margin of 30.7% against -6.0%.
More: Amarin earnings · how Amarin makes money · Zevra Therapeutics earnings · how Zevra Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 28, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.